News

PARTEXIS

 

 

At Animascope, we understand that histopathology significantly contributes to effective evaluation of animal models, biomedical devices, biologicals or small molecule compounds. We also believe that histopathology is essential to the correlation of imaging data to biological changes.

Animascope has established an exclusive partnership with Partexis to provide expert state-of-the-art pathology services for your research and regulatory projects, from the proof of concept stage to pivotal preclinical safety and efficacy evaluations. Partexis offers microscopic evaluation by qualified experimental pathologists that deliver high quality and well-illustrated histopathology reports. Several biotechnology companies, medical device and pharmaceutical firms rely on Partexis cost-effective services and timely support.

   

Research laboratory support

Research laboratory support

   

European Scientific Institute

 

 Animascope is cooperating with the European Scientific Institute for Applied
Physics (ESI in Archamps) and its R&D and Continuing Education departments
for Medical Physics dealing with Nuclear Imaging.

 

   

R&D Tax Credit

Animascope has received the agreement for R&D Tax Credit for 2009 and 2010.
   

Cellvax : Drug Validation Expertise

PRESS RELEASE ANIMASCOPE AND CELLVAX

Animascope and Cellvax to Collaborate on Added Value Services for Disease Animal Models in Therapeutic Areas with Unmet Medical Needs, Including Oncology and Other Severe Human Diseases
 
ANIMASCOPE is a provider of integrated contract research services in the field of pre-clinical, non-invasive biomedical imaging in vivo. ANIMASCOPE's staff has more than ten years of expertise in using X-Ray CT, nuclear imaging (PET / SPECT), magnetic resonance imaging (MRI), ultrasonography and optic imaging techniques to study healthy and disease animal models in various therapeutic fields, including oncology, bones and cardiology.
 
As an established provider of in vitro and in vivo models in oncology and other therapeutic fields (angiogenesis, metastasis, diabetes, CNS, etc.), CELLVAX, a French SME founded in 2001, has consolidated skills in animal modelling for preclinical R&D. In the oncology field CELLVAX offers access to subcutaneous and orthotopic animal xenografts. CELLVAX also offers a range of pre-clinical screenings suitable for the biotechnology and pharmaceutical markets, including toxicology, biodistribution, pharmacokinetic studies, etc.
 
The products and services that ANIMASCOPE and CELLVAX provide complement each other, and so the two companies have signed a collaboration agreement to foster the development and promotion of added value services for disease animal models in therapeutic areas where there are unmet medical needs, including oncology and other severe human diseases.
 
This synergistic collaboration between our two companies will provide more complete and efficient services to our customers and allow the drug development process to be speeded up.
   

Competence Biotech

Animascope is one of the administrators of Competence Biotech, an association devoted to help Biotech companies to hire new cometencies, part time. It is a LEEM (Les Entreprises du Medicament) initiative.

   

Geneva Foundation for Medical Education and Research partner

Animascope is proud to be a Geneva Foundation for Medical Education and Research partner. 

Geneva Foundation for Medical Education and Research is a WHO (World Health Organization) Collaborating Centre in Education and Research in Human Reproduction
   

Site Search